Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

24 May, 2021 | 08:38h | UTC

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection – Nature Medicine

Commentary: Scientists find new way of predicting COVID-19 vaccine efficacy – University of New South Wales

 

Commentary on Twitter (thread – click for more)

 

RCT: Among patients with pemphigus vulgaris, rituximab was superior to mycophenolate mofetil in producing sustained complete remission at 52 weeks (40% vs 10%) but was associated with increased risk of serious adverse events (22% vs. 15%).

24 May, 2021 | 08:24h | UTC

Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris – New England Journal of Medicine

 

M-A: In patients with anaphylaxis, the use of multiple epinephrine doses is necessary in 7.7% of cases.

21 May, 2021 | 08:19h | UTC

Use of multiple epinephrine doses in anaphylaxis: A systematic review and meta-analysis – The Journal of Allergy and Clinical Immunology

Commentary: How Often Does Anaphylaxis Require Redosing of Epinephrine? – Journal Feed

 

FDA In Brief: FDA advises against use of SARS-CoV-2 antibody test results to evaluate immunity or protection from COVID-19, including after vaccination.

20 May, 2021 | 08:55h | UTC

FDA In Brief: FDA Advises Against Use of SARS-CoV-2 Antibody Test Results to Evaluate Immunity or Protection From COVID-19, Including After Vaccination – U.S. Food & Drug Administration

 

Commentary on Twitter (thread – click for more)

 

Characteristics associated with Multisystem Inflammatory Syndrome among adults with SARS-CoV-2 infection

20 May, 2021 | 08:52h | UTC

Characteristics Associated With Multisystem Inflammatory Syndrome Among Adults With SARS-CoV-2 Infection – JAMA Network Open

Editorial: The Multisystem Inflammatory Syndrome in Adults With SARS-CoV-2 Infection—Another Piece of an Expanding Puzzle

Commentary: COVID-related inflammatory syndrome looks different in adults – CIDRAP

 

A pharmacist-led penicillin allergy assessment program can delabel many “penicillin allergic” patients through allergy histories and penicillin skin testing. The program was associated with reduced use of high Clostridioides difficile infection–risk antibiotics.

20 May, 2021 | 08:30h | UTC

Evaluation of a Pharmacist-Led Penicillin Allergy Assessment Program and Allergy Delabeling in a Tertiary Care Hospital – JAMA Network Open

 

Commentaries on Twitter

 

WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.

19 May, 2021 | 08:47h | UTC

International COVID-19 trial to restart with focus on immune responses – Nature

 

COVID vaccines can block variant hitting Asia, lab study finds – “Assays using live SARS-CoV-2 offer hope that the vaccines made by Pfizer and Moderna will protect against a viral strain first seen in India”.

18 May, 2021 | 07:56h | UTC

COVID vaccines can block variant hitting Asia, lab study finds – Nature

See also: Pfizer, Moderna vaccines effective against Indian variants: study – MedicalXpress

 

Commentary on Twitter

 

Systematic review: Treatment of gastro-esophageal reflux disease to help manage asthma in adults and children may result in reduced use of rescue medications, but the benefits on the number of exacerbations and hospital utilization remain uncertain.

18 May, 2021 | 07:27h | UTC

Pharmacological and surgical interventions for the treatment of gastro‐oesophageal reflux in adults and children with asthma – Cochrane Library

Summary: Treatment of gastro-oesophageal reflux disease to help manage asthma in adults and children – Cochrane Library

 

[Preprint] Delaying second Pfizer vaccine dose to 12 weeks increases specific antibody response 3.5-fold in people over 80 years of age.

17 May, 2021 | 08:53h | UTC

BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant – The Lancet

News release: Delaying second Pfizer vaccines to 12 weeks significantly increases antibody responses in older people, finds study – University of Birmingham

Commentaries: Delaying a COVID vaccine’s second dose boosts immune response – Nature AND Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds – Health Policy Watch AND Delay in giving second jabs of Pfizer vaccine improves immunity – The Guardian AND Expert reaction to preprint looking at the immune response in older people after vaccination the Pfizer-BioNTech COVID-19 vaccine with either a 3-week or a 12-week dosing schedule – Science Media Centre

 

‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo.

17 May, 2021 | 08:45h | UTC

‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo – STAT

Related: COVID-19 Vaccines in Patients With Cancer—A Welcome Addition, but There Is Need for Optimization – JAMA Oncology

 

Perspective | New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications.

14 May, 2021 | 08:43h | UTC

New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications – New England Journal of Medicine

 

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

14 May, 2021 | 08:46h | UTC

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data – The Lancet

Commentaries: More side effects noted after using 2 different COVID vaccines – CIDRAP AND Covid vaccines: Mixing increases reports of mild side-effects – BBC

 

Perspective | Vaccines seem to work well against coronavirus variants. It’s also complicated.

14 May, 2021 | 08:41h | UTC

Vaccines seem to work well against coronavirus variants. It’s also complicated – STAT

 

Review: How to interpret and use COVID-19 serology and immunology tests.

14 May, 2021 | 08:36h | UTC

How to interpret and use COVID-19 serology and immunology tests – Clinical Microbiology and Infection

 

Systematic review: Combination fixed‐dose beta-agonist and steroid inhaler as required is clinically effective in adults and adolescents with mild asthma.

14 May, 2021 | 08:23h | UTC

Combination fixed‐dose beta agonist and steroid inhaler as required for adults or children with mild asthma – Cochrane Library

Summary: Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma – Cochrane Library

 

RCT: Tezepelumab can reduce exacerbations in adults and adolescents with severe, uncontrolled asthma.

14 May, 2021 | 08:25h | UTC

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma – New England Journal of Medicine

Commentary: New drug shows promise against tough-to-manage asthma – MedicalXpress

 

Practice Guideline: Prevention and management of allergic reactions to food in child care centers and schools

11 May, 2021 | 09:06h | UTC

Prevention and management of allergic reactions to food in child care centers and schools: Practice guideline – Journal of Allergy and Clinical Immunology

 

Commentary on Twitter (thread – click for more)

 

Covid-19: Most people admitted to hospital after vaccination were infected before immunity could develop, research shows.

10 May, 2021 | 01:14h | UTC

Covid-19: Most people admitted to hospital after vaccination were infected before immunity could develop, research shows – The BMJ

 

Commentary on Twitter

 

Cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S. 11 excess venous thromboembolic events per 100 000 vaccinations; 2.5 excess cerebral venous thrombosis per 100 000 vaccinations.

7 May, 2021 | 08:33h | UTC

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study – The BMJ

Editorial: Thromboembolism and the Oxford-AstraZeneca vaccine – The BMJ

Commentaries: Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination – The BMJ Opinion AND Putting risks into context: covid-19 vaccines and blood clots – The BMJ Opinion AND Expert reaction to study from Denmark and Norway looking at rare blood clots after the Oxford-AstraZeneca vaccine – Science Media Centre

 

Commentary on Twitter

 

The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

7 May, 2021 | 08:30h | UTC

The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity – The Lancet Respiratory Medicine

 

Commentary on Twitter

 

Cohort study shows inadequate antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients.

6 May, 2021 | 09:01h | UTC

Antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients – Prospective cohort study – Clinical Microbiology and Infection

 

Commentary on Twitter

 

Observational study in Qatar: Pfizer–BioNTech Covid vaccine is 89.5% effective against B.1.1.7 variant and 75.0% effective against B.1.351 variant. Vaccine effectiveness against severe, critical, or fatal disease with any SARS-CoV-2 variant was very high, at 97.4%.

6 May, 2021 | 09:06h | UTC

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants – New England Journal of Medicine

Commentary: Pfizer-BioNTech vaccine offers strong protection against key variants of concern, real-world data from Qatar shows – The Washington Post

 

Commentary on Twitter

 

Organ transplant recipients remain vulnerable to Covid-19 even after second vaccine dose.

6 May, 2021 | 09:03h | UTC

Organ Transplant Recipients Remain Vulnerable to Covid-19 Even After Second Vaccine Dose – Johns Hopkins Medicine

Original Study: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients – JAMA

 

[Preprint] SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity

5 May, 2021 | 08:40h | UTC

SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity – medRxiv

Commentary: SARS-CoV-2 antibodies are detectable up to a year after infection, finds study – News Medical

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.